Journal of Clinical Medicine (May 2020)

Management and Survival of Elderly and Very Elderly Patients with Ovarian Cancer: An Age-Stratified Study of 1123 Women from the FRANCOGYN Group

  • Yolaine Joueidi,
  • Ludivine Dion,
  • Sofiane Bendifallah,
  • Camille Mimoun,
  • Alexandre Bricou,
  • Krystel Nyangoh Timoh,
  • Pierre Collinet,
  • Cyril Touboul,
  • Lobna Ouldamer,
  • Henri Azaïs,
  • Yohann Dabi,
  • Cherif Akladios,
  • Geoffroy Canlorbe,
  • Pierre-Adrien Bolze,
  • Hélène Costaz,
  • Mathieu Mezzadri,
  • Tristan Gauthier,
  • Frederic Kridelka,
  • Pauline Chauvet,
  • Nicolas Bourdel,
  • Martin Koskas,
  • Xavier Carcopino,
  • Emilie Raimond,
  • Olivier Graesslin,
  • Lise Lecointre,
  • Marcos Ballester,
  • Cyrille Huchon,
  • Jean Levêque,
  • Vincent Lavoué

DOI
https://doi.org/10.3390/jcm9051451
Journal volume & issue
Vol. 9, no. 5
p. 1451

Abstract

Read online

Elderly women with ovarian cancer are often undertreated due to a perception of frailty. We aimed to evaluate the management of young, elderly and very elderly patients and its impact on survival in a retrospective multicenter study of women with ovarian cancer between 2007 to 2015. We included 979 women: 615 women (62.8%) p = 0.048). Patients >65 years had more >IIa FIGO stage: 76% for p = 0.033). Women ≥75 years had less standard procedures (40% (34/84) vs. 59% (104/177) for 65–74 years and 72% (384/530) for p 8 compared with 16% and 22% for the other groups (p p p = 0.003). Univariate analysis for 3-year Overall Survival showed that age >65 years, FIGO III (HR = 3.702, 95%CI: 2.30–5.95) and IV (HR = 6.318, 95%CI: 3.70–10.77) (p p p 65 years are more likely to have incomplete surgery and more residual disease despite more advanced ovarian cancer. These elements are prognostic factors for women’s survival regardless of age. Specific trials in the elderly would produce evidence-based medicine and guidelines for ovarian cancer management in this population.

Keywords